Newborn Jaundice Treatment Reduces Light Therapy 70%

A Newborn Jaundice Approach Promises Less Light Therapy, Lower Costs

A major Italian hospital tested the newest American guidelines for treating newborn jaundice against their current national standard. The results, published in the European Journal of Pediatrics, suggest that adopting the updated approach could safely reduce medical interventions for infants by nearly 70% and significantly cut healthcare costs.

Reassessing the Risk to Avoid Unnecessary Treatment

Neonatal hyperbilirubinemia, or jaundice, causes a newborn’s skin and eyes to appear yellow due to a buildup of bilirubin. While high levels can be toxic to the developing brain, a landmark shift in pediatric thinking has occurred. Research now indicates that the threat of bilirubin-induced neurological damage (BIND) in otherwise healthy term and near-term infants was overestimated in older medical guidelines. The 2022 AAP guidelines reflect this, raising the bilirubin level at which treatment is recommended for low-risk babies.

The study from Spedali Civili Children’s Hospital in Brescia, led by Dr. F.M. Risso and Dr. S. Pintaldi, put this theory to a practical test. They took 904 newborns managed under Italy’s existing protocols from late 2024 to early 2025 and retrospectively applied the AAP’s 2022 criteria. The median bilirubin check happened around 51 hours after birth, a critical window for decision-making. The team then compared the clinical actions that would have been taken under each set of rules.

A 70% Drop in Phototherapy with a Shift to Outpatient Monitoring

The difference was stark. Using the new American guidelines would have slashed the use of phototherapy—the standard treatment where babies are placed under special blue lights—by 69.8%. For this cohort, that translated to 98 fewer days spent in hospital beds receiving light treatment.

This reduction is not about neglecting care, but about applying a more precise filter. “The AAP revised its hyperbilirubinemia guidelines, providing higher hourly bilirubin thresholds for newborns without risk factors for BIND,” the authors note. The guidelines more carefully distinguish between infants with health concerns and those who are robust, reserving intervention for those who truly need it.

Care does not disappear; it changes location. The simulation showed a 37.9% increase in post-discharge bilirubin checks. This represents a strategic shift from inpatient treatment to vigilant outpatient surveillance, a model that trusts careful monitoring after families go home.

Economic and Organisational Rationale for Change

Beyond clinical impact, the hospital’s health management analysts calculated the financial and operational effects. Adopting the AAP 2022 guidelines would have reduced variable costs by €16,591.58 in just the four-month study period. The savings come primarily from fewer days of phototherapy, which consumes nursing time, equipment, and bed space.

These “analytical outcomes encouraged the adoption of the AAP guidelines at our centre,” the paper states. The move represents a clear opportunity for resource rationalisation—freeing up neonatal unit capacity for sicker infants while maintaining safety. However, the researchers are not declaring immediate victory. They caution that “longitudinal surveillance will clarify the safety and actual extent of this change,” acknowledging that real-world implementation must be watched closely.

Implications for Parents and Pediatric Care Systems

For parents, this evolving evidence means that a common newborn condition may be managed with less medical intervention. Seeing a baby under bright lights can be stressful; reducing unnecessary phototherapy supports early bonding and less disrupted feeding. It underscores the importance of identifying risk factors—like prematurity, blood type incompatibility, or poor feeding—which remain central to safe care under any guideline.

Globally, the study adds weight to a movement toward more conservative jaundice management in well infants. Hospitals and health systems evaluating their own protocols, as Italy is now doing on a facility-by-facility basis, can look to this real-world simulation for evidence of both safety and efficiency gains. It exemplifies how evidence-based practice evolves: not by adding technology, but by refining thresholds and trusting natural physiology when science supports it.

A single hospital’s analysis shows that updating jaundice care based on modern evidence can drastically reduce treatment rates and costs without compromising safety. The change hinges on better risk stratification and moving care from the hospital to the home with confident monitoring. This approach prioritizes the well-being of the infant while making smarter use of healthcare resources.

Sources:
https://pubmed.ncbi.nlm.nih.gov/42213232/
https://pubmed.ncbi.nlm.nih.gov/42212814/
https://pubmed.ncbi.nlm.nih.gov/42200327/